RRR schreef op 8 maart 2016 15:34:
HAE patients previously dependent on plasma derived C1INH therapies, including adolescents, will be able to receive RUCONEST® with the benefit of eliminating risks of exposure to known blood borne pathogens, such as Hepatitis A, B, C, E, HIV, and CJD, as well as continuously (re)-emerging pathogens, such as the recent ZIKA virus.”
Met dank aan Hans T. (van erikerik)
Dit is belangrijk mensen...dit is een reden waarom Recombinant ook in de HAE sector het gaat winnen.